Modified Cells Resist Steroid, Calcineurin Inhibitors
Summary
The USPTO has published patent application US20260108610A1 for modified cells designed to resist steroid and calcineurin inhibitor drugs, with inventors Mark J. Osborn, Keli Hippen, and Bruce R. Blazar named in the filing. The application covers pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells (including modified Tregs) with resistance mechanisms to immunosuppressive drugs. The application was filed June 30, 2025 and published April 23, 2026.
“The present disclosure provides modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells (e.g., modified Tregs) that are steroid and/or calcineurin inhibitor-resistant.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO has published patent application US20260108610A1 for modified cells with resistance to steroid and calcineurin inhibitor drugs, covering pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells such as modified Tregs.
This publication establishes intellectual property protection for a cell engineering approach relevant to transplant and autoimmune therapies. Organizations developing competing immunosuppression methods or related cell-based treatments should assess their freedom to operate. Potential licensees may evaluate the therapeutic potential and commercial viability of the modified cells described.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Drug-Resistant Immune Cells and Methods of Use Thereof
Application US20260108610A1 Kind: A1 Apr 23, 2026
Inventors
Mark J. Osborn, Keli Hippen, Bruce R. Blazar
Abstract
The present disclosure provides modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells (e.g., modified Tregs) that are steroid and/or calcineurin inhibitor-resistant. The present disclosure provides methods for generating steroid and/or calcineurin inhibitor-resistant modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells. Also provided herein are compositions and methods of treatment.
CPC Classifications
A61K 45/06 A61K 31/436 A61K 31/573 A61K 35/28 A61K 38/13 A61K 40/10 A61K 40/11 A61K 40/22 A61K 40/418 A61P 37/06 C07K 14/705 C12N 5/0637 C12N 9/16 C12N 9/22 C12N 15/11 C12N 15/907 C12Y 301/03016 A61K 2239/31 A61K 2239/38 C12N 2310/20 C12N 2800/80
Filing Date
2025-06-30
Application No.
19255339
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.